Health and Healthcare

Why One Analyst Sees Sarepta's Roche Deal Taking Off

Pattanaphong Khuankaew / Getty Images

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this stock as a result of the deal.

The deal provides Roche exclusive commercial rights to SRP-9001, Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD), outside the United States.

Under the agreement, Sarepta will receive $1.15 billion in an upfront payment and an equity investment. The company will receive up to $1.7 billion in regulatory and sales milestones, and royalties on net sales, which are anticipated to be in the mid-teen percentages. Additionally, Roche and Sarepta will share equally global development expenses. Sarepta will retain all rights to SRP-9001 in the United States.

Also, Sarepta will continue to be responsible for the global development plan and manufacturing build-out for SRP-9001. Sarepta also has granted Roche an option to acquire ex-U.S. rights to certain future DMD-specific programs, in exchange for separate milestone and royalty considerations and cost sharing.

As a result, Janney reiterated a Buy rating for Sarepta with a $185 price target, implying an upside of 42% from the most recent closing price of $129.77.

Ultimately, the firm believes that the partnership with Roche should allow Sarepta to focus on the U.S. market with both commercialization and clinical development of a robust pipeline, while benefiting from Roche’s global footprint, which should bring SRP-9001 to a significantly larger number of DMD patients that otherwise would be difficult to reach.

On the number’s side, Sarepta ended the third quarter with cash, cash equivalents and investments of roughly $1.1 billion, and the company raised $250 million through a senior secured loan earlier this month. Management expects to have over $2.5 billion of cash after the completion of the transaction. The cost-sharing structure of the agreement should also relieve a significant burden associated with the clinical development of SRP-9001 from Sarepta.

Shares of Sarepta were last seen at $129.68, in a 52-week range of $72.05 to $158.80. The consensus price target is $196.05.


Credit card companies are handing out rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.